Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells

Leukemia

Volumn 26, Issue 6, 2012, Pages 1407-1410

  Bar Natan, M ^a,b   Nelson, E A ^a   Walker, S R ^a   Kuang, Y ^a   Distel, R J ^a   Frank, D A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PIMOZIDE; PROPIDIUM IODIDE; PROTEIN BCL XL; PROTEIN MCL 1; STAT5 PROTEIN;

CELL CYCLE PROGRESSION; CELL SURVIVAL; DISEASE CONTROL; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL LINE; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84862000598     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.338     Document Type: Letter

References (14)

1. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190-2198.
2. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006; 63: 2939-2953. (Pubitemid 46072300)
3. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-4281. (Pubitemid 43801351)
4. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-1668. (Pubitemid 47086756)
5. Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 2009; 23: 1708-1715.
6. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
7. Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ et al. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 2009; 147: 495-506.
8. Nelson EA, Frank DA. Developing pharmacological modulators of STAT signaling. In: Stephanou A (ed). JAK-STAT Pathway in Disease. Landes Bioscience: Austin, 2009, pp 164-172.
9. Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 2010; 285: 5296-5307.
10. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421-3429.
11. Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res 2009; 69: 5987-5995.
12. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19: 5662-5679.
13. Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J et al. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem 2008; 283: 32334-32343.
14. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009; 114: 5034-5043.